메뉴 건너뛰기




Volumn 5, Issue 1, 2011, Pages 291-298

Efficacy and tolerability of the fixed combination of brinzolamide 1% and timolol 0.5% in daily practice

Author keywords

Brinzolamide; Fixed combination; Glaucoma; Intraocular pressure; Timolol

Indexed keywords

ANTIGLAUCOMA AGENT; BIMATOPROST PLUS TIMOLOL; BRINZOLAMIDE PLUS TIMOLOL; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST PLUS TIMOLOL; TAFLUPROST PLUS TIMOLOL; TIMOLOL PLUS TRAVOPROST; UNCLASSIFIED DRUG;

EID: 79952844744     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S16355     Document Type: Article
Times cited : (26)

References (11)
  • 1
    • 79952821291 scopus 로고    scopus 로고
    • Summary of Product Characteristics (SPC) Azarga®
    • Summary of Product Characteristics (SPC) Azarga®. Alcon Pharma, 2008.
    • (2008) Alcon Pharma
  • 2
    • 0345337696 scopus 로고    scopus 로고
    • Bundesinstitut fur Arzneimittel und Medizinprodukte website, Accessed September 24, 2010
    • Bundesinstitut fur Arzneimittel und Medizinprodukte website. Arzneimittelgesetz (AMG). http://www.bfarm.de/EN/BfArM/BfArMService/AMG_en/amg-node-en.html. Accessed September 24, 2010.
    • Arzneimittelgesetz (AMG)
  • 3
    • 74549215576 scopus 로고    scopus 로고
    • Repeatability and reproducibility for intraocular pressure measurement by dynamic contour, ocular response analyzer, and goldmann applanation tonometry
    • Sullivan-Mee M, Gerhardt G, Halverson KD, Qualls C. Repeatability and reproducibility for intraocular pressure measurement by dynamic contour, ocular response analyzer, and goldmann applanation tonometry. J Glaucoma. 2009;18(9):666-673.
    • (2009) J Glaucoma , vol.18 , Issue.9 , pp. 666-673
    • Sullivan-Mee, M.1    Gerhardt, G.2    Halverson, K.D.3    Qualls, C.4
  • 5
    • 79952826677 scopus 로고    scopus 로고
    • Whitehouse Station, NJ: Merck & Co., Inc
    • COSOPT [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2006.
    • (2006) COSOPT [package Insert]
  • 6
    • 57349119300 scopus 로고    scopus 로고
    • A one-week comfort study of BID-dosed brinzolamide 1%/timolol 0.5% ophthalmic suspension fixed combination compared to BID-dosed dorzolamide 2%/timolol 0.5% ophthalmic solution in patients with open-angle glaucoma or ocular hypertension
    • for the Brinzolamide/Timolol Comfort Study Group
    • Vold SD, Evans RM, Stewart RH, et al; for the Brinzolamide/Timolol Comfort Study Group. A one-week comfort study of BID-dosed brinzolamide 1%/timolol 0.5% ophthalmic suspension fixed combination compared to BID-dosed dorzolamide 2%/timolol 0.5% ophthalmic solution in patients with open-angle glaucoma or ocular hypertension. J Ocul Pharm Ther. 2008;24(6):601-605.
    • (2008) J Ocul Pharm Ther , vol.24 , Issue.6 , pp. 601-605
    • Vold, S.D.1    Evans, R.M.2    Stewart, R.H.3
  • 7
    • 67651183720 scopus 로고    scopus 로고
    • The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension
    • Manni G, Denis P, Chew P, et al. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2009;18(4):293-300.
    • (2009) J Glaucoma , vol.18 , Issue.4 , pp. 293-300
    • Manni, G.1    Denis, P.2    Chew, P.3
  • 8
    • 77955380703 scopus 로고    scopus 로고
    • Factors related to glaucoma treatment compliance: Patients' opinions from a university hospital
    • Silva LR, de Paula JS, Rocha EM, Rodrigues Mde L. Factors related to glaucoma treatment compliance: patients' opinions from a university hospital. Arq Bras Oftalmol. 2010;73(2):116-119.
    • (2010) Arq Bras Oftalmol , vol.73 , Issue.2 , pp. 116-119
    • Silva, L.R.1    de Paula, J.S.2    Rocha, E.M.3    Rodrigues, M.L.4
  • 9
    • 35848945084 scopus 로고    scopus 로고
    • Ocular comfort of combination glaucoma therapies: Brimonidine 0.2%/timolol 0.5% compared with dorzolamide 2%/timolol 0.5%
    • Chan K, Testa M, McCluskey P. Ocular comfort of combination glaucoma therapies: brimonidine 0.2%/timolol 0.5% compared with dorzolamide 2%/timolol 0.5%. J Ocul Pharmacol Ther. 2007;23(4): 372-376.
    • (2007) J Ocul Pharmacol Ther , vol.23 , Issue.4 , pp. 372-376
    • Chan, K.1    Testa, M.2    McCluskey, P.3
  • 10
    • 0141928070 scopus 로고    scopus 로고
    • Compliance barriers in glaucoma: A systematic classification
    • Tsai JC, McClure CA, Ramos SE, et al. Compliance barriers in glaucoma: a systematic classification. J Glaucoma. 2003;12(5):393-398.
    • (2003) J Glaucoma , vol.12 , Issue.5 , pp. 393-398
    • Tsai, J.C.1    McClure, C.A.2    Ramos, S.E.3
  • 11
    • 0033736217 scopus 로고    scopus 로고
    • Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting
    • Barnebey H, Kwok SY. Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting. Clin Ther. 2000;22(10):1204-1212.
    • (2000) Clin Ther , vol.22 , Issue.10 , pp. 1204-1212
    • Barnebey, H.1    Kwok, S.Y.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.